As of November 7, 2026, Passage BIO, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on November 6, 2026 (Form 8-K, November 6, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Passage BIO, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Passage BIO, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-11-06. Every row below is cited to the filing it comes from, and this page adds each new change as Passage BIO, Inc. files it.
Layoffs on record: 1 filing or notice, latest 2026-04-28 (layoff filings and notices).
Also on the record for Passage BIO, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G/A, by Vestal Point Capital, LP | — | 5%+ stakes | Source |
| July 2, 2026 | Stake report, Schedule 13D, by Lynx1 Capital Management LP | 21% of the class | 5%+ stakes | Source |
| June 25, 2026 | Stake report, Schedule 13G, by Baselake Partners, LP | 7.3% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by LYNX1 CAPITAL MANAGEMENT LP | 19.6% of the class | 5%+ stakes | Source |
| July 24, 2025 | Stake report, Schedule 13D/A, by ORBIMED ADVISORS LLC | 4.25% of the class | 5%+ stakes | Source |
| July 21, 2025 | Stake report, Schedule 13D/A, by ORBIMED ADVISORS LLC | 7.82% of the class | 5%+ stakes | Source |
| July 9, 2025 | Stake report, Schedule 13D/A, by ORBIMED ADVISORS LLC | 9.5% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Passage BIO, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Passage BIO, Inc. and the records around it.
Passage BIO, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Layoff notices Apr 2026
- Who owns it
Companies that share a holder
- Baselake Partners, LP also filed stake reports on 7 other companies: KIORA PHARMACEUTICALS, INC. (Sep 2026), Generation Bio Co. (Feb 2026), Athira Pharma, Inc. (Feb 2026)
- Lynx1 Capital Management LP also filed stake reports on 11 other companies: C4 Therapeutics, Inc. (Aug 2026), GH Research PLC (Aug 2026), iBio, Inc. (Aug 2026)
- Vestal Point Capital, LP also filed stake reports on 27 other companies: Alto Neuroscience, Inc. (Aug 2026), iBio, Inc. (Aug 2026), Immunocore Holdings plc (Aug 2026)
Watch Passage BIO, Inc.
Get an email when Passage BIO, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Passage BIO, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Passage BIO, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Passage BIO, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-11-06 | Reported | not named in the filing | 8-K, 2026-11-06 |
New leaders reset buying decisions — get the Full Report on Passage BIO, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Passage BIO, Inc., with the record behind each one.
Find candidates like senior executive at Passage BIO, Inc.Every change, in the filing's words
Reported
At the Special Meeting, Passage Bio's stockholders considered and approved the Remix Therapeutics, Inc. (" Remix ") 2026 Equity Incentive Plan (the " 2026 Plan "), which will become effective at the effective time of the First Merger (as defined below) (the " Initial Effective Time ") and is contingent on the completion of the First Merger.
- 2026 Equity Incentive Plan On November 5, 2026, Passage Bio, Inc. ("Passage Bio") held a Special Meeting of Stockholders (the "Special Meeting").
- The 2026 Plan is intended to replace Passage Bio's 2018 Equity Incentive Plan (the "2018 EIP"), Passage Bio's 2020 Equity Incentive Plan (the "2020 EIP"), and Remix's 2019 Equity Incentive Plan (the "Remix 2019 Plan," together with the 2018 EIP and 2020 EIP, the "Prior Plans").
- The Remix 2019 Plan, together with all outstanding awards thereunder, will be assumed by Passage Bio in the First Merger.
- No more than 17,317,500 shares (before giving effect to the proposed Reverse Stock Split) may be issued under the 2026 Plan upon the exercise of incentive stock options.
- Under the terms of the Merger Agreement (as defined below), at the Initial Effective Time, each Remix stock option that is outstanding and unexercised immediately prior to the Initial Effective Time under the Remix 2019 Plan will automatically be converted into an option to purchase shares of Passage Bio Common Stock (as defined below) based on the assumed exchange ratio of 0.1727 (subject to adjustment for the effect of the proposed Reverse Stock Split).
- Shares issued under the 2026 Plan may be authorized but unissued shares, including shares authorized but unissued under the Prior Plans, shares purchased on the open market, or treasury shares.
Tools for this story
Each opens in a new tab, filled in for Passage BIO, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.